People: Sarepta Therapeutics Inc (SRPT.W)

Summary

Name	Age	Since	Current Position
William Goolsbee	58	2010	Independent Chairman of the Board
Christopher Garabedian	45	2012	President, Chief Executive Officer, Director
Sandy Mahatme	47	2012	Chief Financial Officer, Senior Vice President
David Howton		2012	Senior Vice President, General Counsel
Edward Kaye	63	2011	Senior Vice President, Chief Medical Officer
Michael Jacobsen	54	2012	Vice President - Finance, Principal Accounting Officer, Secretary
M. Kathleen Behrens	59	2009	Independent Director
Anthony Chase	57	2010	Independent Director
John Hodgman	58	2004	Independent Director
Gil Price	56	2007	Independent Director
Hans Wigzell	74	2010	Independent Director
Erin Cox		2012	IR Contact

» Insider Trading

Biographies

Name	Description
William Goolsbee	Mr. William A. Goolsbee is Independent Chairman of the Board of Sarepta Therapeutics, Inc., since June 2010. He has served as a member of board of directors since October 2007. He also serves as a member of the audit committee and the compensation committee. Mr. Goolsbee was founder, chairman and Chief Executive Officer of Horizon Medical Inc. from 1987 until its acquisition by a unit of UBS Private Equity in 2002. Mr. Goolsbee was a founding director of ImmunoTherapy Corporation in 1993, becoming chairman of the board in 1995, a position he held until overseeing the acquisition of ImmunoTherapy by AVI BioPharma, Inc. in 1998. His experience prior to 1987 includes a series of increasingly responsible executive positions with CooperVision Inc. and Cooper Laboratories Inc. Mr. Goolsbee holds a B.A. degree from the University of California at Santa Barbara. Mr. Goolsbee served as Chairman of privately held BMG Pharma LLC from 2006 through 2011 and presently serves as Chairman and Chief Executive Officer of BMG Hematology LLC, a product development and licensing company.
Christopher Garabedian	Mr. Christopher Garabedian is President, Chief Executive Officer and Director of Sarepta Therapeutics, Inc. He resigned as Principal Financial Officer of the company effective November 05, 2012. He has been a member of board of directors since June 2010 and President and Chief Executive Officer since January 2011. Mr. Garabedian served as Vice President of Corporate Strategy for Celgene Corporation, a publicly-traded integrated global biopharmaceutical company, from July 2007 to December 2010, where he was responsible for assessing all potential business development transactions. From November 2005 to June 2007, Mr. Garabedian served as an independent consultant to early-stage biopharmaceutical companies. From 1997 to 1998 and from 1999 to November 2005, Mr. Garabedian worked at Gilead Sciences, Inc., a publicly-traded biopharmaceutical company, where he served in a number of global leadership roles, including as Vice President of Corporate Development, Vice President of Marketing, and Vice President of Medical Affairs. While at Gilead Sciences, Mr. Garabedian’s responsibilities included managing corporate development initiatives, including portfolio review and planning, mergers and acquisitions and in-licensing activities, and four global product launches. Mr. Garabedian also held various commercial roles at COR Therapeutics, Inc. from 1998 to 1999 and at Abbott Laboratories from 1994 to 1997. He started his biopharmaceutical career as a consultant with Migliara/Kaplan Associates from 1991 to 1994. Mr. Garabedian received his B.S. in marketing from the University of Maryland.
Sandy Mahatme	Mr. Sandy Mahatme has been appointed as Chief Financial Officer, Senior Vice President of Sarepta Therapeutics Inc. effective November 05, 2012. Mr. Mahatme joined the Company from Celgene Corporation, a biopharmaceutical company, where from January 2006 to November 2012, he served in various roles, including Senior Vice President of Corporate Development, Corporate Treasurer and Senior Vice President of Tax. While at Celgene, Mr. Mahatme built the treasury and tax functions before establishing the Corporate Development Department, focused on strategic, targeted initiatives including emerging markets, acquisitions and licensing and strategic planning. Prior to working at Celgene, Mr. Mahatme worked for Pfizer Inc., a pharmaceutical company, for eight and a half years in senior roles in Business Development and Corporate Tax. Mr. Mahatme started his career at Ernst & Young LLP where he advised multinational corporations on a broad range of transactions. Mr. Mahatme holds Master of Laws (LL.M.) degrees from Cornell Law School and NYU School of Law and is a member of the New York State Bar Association.
David Howton	Mr. David Tyronne Howton is appointed as the Senior Vice President, General Counsel of Sarepta Therapeutics, Inc. Mr. Howton joins Sarepta from Vertex Pharmaceuticals where he was the senior vice president, chief legal officer and a member of the executive team. In that capacity, Mr. Howton participated in the general management of the company and oversaw all aspects of the Vertex global legal and compliance departments. Prior to his appointment as chief legal officer in 2011, Mr. Howton served as the chief compliance officer and was responsible for designing and implementing the Vertex corporate compliance program as well as chairing the company’s Corporate Compliance Committee. Mr. Howton joined Vertex in 2009 from Genentech where he served in a number of legal roles before becoming the company’s chief healthcare compliance officer. Prior to joining Genentech Inc. in 2003, Mr. Howton was a member of the Sidley Austin LLP corporate healthcare practice where he advised on corporate transactions involving life science companies and provided regulatory counsel. Mr. Howton holds a B.A. from Yale University and a J.D. from Northwestern University School of Law.
Edward Kaye	Dr. Edward M. Kaye, M.D., is Senior Vice President, Chief Medical Officer of Sarepta Therapeutics, Inc., since June 2011. Dr. Kaye was Group Vice President of Clinical Development at Genzyme Corporation from April 2007 to June 2011, where he supervised the clinical research in the lysosomal storage disease programs and in the genetic neurological disorders. Prior to this, Dr. Kaye held various roles at Genzyme Corporation since 2001, including Vice President of Medical Affairs for Lysosomal Storage Diseases, Vice President of Clinical Research and Interim Head of PGH Global Medical Affairs. Dr. Kaye earned his B.S. in Biology from Loyola University and earned his M.D. at Loyola University Stritch School of Medicine. He received his Pediatric training at Loyola University Hospital, Child Neurology training at the Boston City Hospital, Boston University, and completed his training as a Neurochemical Research Fellow (Geriatric Fellow) at the Bedford VA Hospital, Boston University. In 1998, Dr. Kaye accepted the appointment as Chief of Biochemical Genetics at the Children’s Hospital of Philadelphia and Associate Professor of Neurology and Pediatrics at the University of Pennsylvania School of Medicine until moving to Genzyme Corporation at the end of 2001. Dr. Kaye continues as a Neurological Consultant at the Children’s Hospital of Boston and is on the editorial boards of a number of journals including Journal of Child Neurology and Pediatric Neurology. He also previously served on the board of Annals of Neurology. Dr. Kaye is also on the Medical/Scientific Advisory Boards of the United Leukodystrophy Foundation, Spinal Muscular Atrophy Foundation, CureCMD, CureDuchenne, and the Prize4Life.
Michael Jacobsen	Mr. Michael A. Jacobsen is Vice President - Finance, Principal Accounting Officer, Secretary of Sarepta Therapeutics, Inc. He has served as Vice President of Finance and Principal Accounting Officer since September 2011 and as Secretary since February 2012. Mr. Jacobsen was Vice President and Chief Accounting Officer at ZymoGenetics, Inc., a publicly-traded biotechnology company acquired by Bristol-Myers Squibb, BMS, in October 2010, from April 2007 to August 2011, where his responsibilities included managing all aspects of accounting and financial information, tax planning and compliance, SEC reporting, annual audit and quarterly reviews, and purchasing. Subsequent to the merger, Mr. Jacobsen was responsible for migrating the ZymoGenetics financial operations and systems to BMS. Prior to this, Mr. Jacobsen held various roles at ICOS Corporation, a publicly-traded biotechnology company acquired by Eli Lilly in January 2007, from October 2001 to April 2007, including Senior Director of Finance and Corporate Controller. From April 1995 to October 2001, Mr. Jacobsen held Vice President of Finance or Chief Financial Officer roles at three companies in the software, computer hardware and internet retailing industries, two of which were publicly traded. Mr. Jacobsen is a certified public accountant and received his bachelor’s degree in accounting from Idaho State University.
M. Kathleen Behrens	Dr. M. Kathleen Behrens, Ph.D., is Independent Director of Sarepta Therapeutics, Inc., since March 2009. She also serves as chairwoman of the nominating and corporate governance committee and as a member of the compensation committee. Dr. Behrens served as a member of the President’s Council of Advisors on Science and Technology (“PCAST”) from 2001 to early 2009 and as chairwoman of PCAST’s Subcommittee on Personalized Medicine. She has served as a public-market biotechnology securities analyst as well as a venture capitalist focusing on healthcare, technology and related investments. She was instrumental in the founding of several biotechnology companies including Protein Design Labs, Inc. and COR Therapeutics, Inc. She worked for Robertson Stephens & Co. from 1983 through 1996, serving as a general partner and managing director. Dr. Behrens continued in her capacity as a general partner for selected venture funds for RS Investments from 1996 through 2009, after management led a buyout of that firm from Bank of America. From 1997 to 2005, she was a director of the Board on Science, Technology and Economic Policy for the National Research Council, and from 1993 to 2000 she was a director, president, and chairwoman of the National Venture Capital Association. Since 2009, Dr. Behrens has worked as an independent life sciences consultant and investor. Dr. Behrens is also a director of Amylin Pharmaceuticals, Inc. Dr. Behrens holds a B.S. in Biology and a Ph.D. in Microbiology from the University of California, Davis.
Anthony Chase	Mr. Anthony R. Chase is Independent Director of Sarepta Therapeutics, Inc., since April 2010. He also serves as a member of the audit committee and the nominating and corporate governance committee. Mr. Chase serves as chairman of ChaseSource, L.P., a position he has held since October 2006, and ChaseSource Real Estate Services, L.P., a position he has held since January 2008. Previously, he was Chairman and Chief Executive Officer of ChaseCom, L.P. from January 1997 to December 2007, when ChaseCom, L.P. was acquired by AT&T. Mr. Chase is a tenured Professor at the University of Houston Law Center where he began teaching in 1990. Mr. Chase is a member of the American Bar Association and State Bar of Texas. Mr. Chase is a director of Western Gas Partners (NYSE) and, in the past five years, has served as a director of the Cornell Companies, Inc. He is a member of the Council on Foreign Relations. Mr. Chase received an A.B., with honors, from Harvard College, received a J.D. from Harvard Law School, and received an M.B.A. from Harvard Business School.
John Hodgman	Mr. John C. Hodgman is Independent Director of Sarepta Therapeutics, Inc., since March 2004. He also serves as the chairman of the audit committee and as a member of the compensation committee. In the past five years, Mr. Hodgman has also served as a director of Cygnus, Inc. He has served as the Senior Vice President of Finance and Chief Financial Officer of InterMune, Inc., a biotechnology company, since August 2006. He served as the Chairman of Cygnus, Inc., a biopharmaceutical company, from 1999 to 2008, and as President and Chief Executive Officer of that company between 1998 and 2006. Mr. Hodgman joined Cygnus in 1994 as Vice President of Finance and Chief Financial Officer, and between 1995 and 1998, he also served as president of Cygnus Diagnostics. He was President and Chief Executive Officer of Aerogen, Inc., a biopharmaceutical company, from June 2005 to October 2005 when that company was sold to Nektar, Inc. Mr. Hodgman holds a B.S. degree from Brigham Young University and an M.B.A. from the University of Utah. Mr. Hodgman is a director of Immersion Corporation.
Gil Price	Dr. Gil Price, M.D., is Independent Director of Sarepta Therapeutics, Inc., since October 30, 2007. He also serves as the chairman of the compensation committee and as a member of the nominating and corporate governance committee. Dr. Price is a clinical physician trained in internal medicine with a long-standing interest in drug development, adverse drug reactions, drug utilization and regulation. Since 2002, he has been the Chief Executive Officer and Chief Medical Officer of Drug Safety Solutions, a provider of solutions for clinical and drug safety operations. From 1997 to 2002, Dr. Price was the director of clinical development for oncology at MedImmune, Inc., the biologics subsidiary of AstraZeneca. Prior to joining MedImmune, Dr. Price worked in the contract research organization sector. Dr. Price began his pharmaceutical career at GlaxoSmithKline Inc., where he worked for nearly nine years on both the commercial and research sides of that company. Dr. Price is a member of the American Medical Association, the Academy of Pharmaceutical Physicians and a past member of the American Society for Microbiology. Dr. Price received a B.A. from the University of Rio Grande and a M.D. from the University of Santiago.
Hans Wigzell	Dr. Hans Wigzell, M.D., Ph.D., is Independent Director of Sarepta Therapeutics, Inc., since June 2010. In the past five years, Dr. Wigzell has served as a director of Probi AB and Diamyd Medical AB and currently serves as a director of RaySearch Laboratories AB, Sobi AB, and Intercell AG. Since 2006, Dr. Wigzell has served as chairman of Karolinska Development AB, a company listed on the NASDAQ OMX Stockholm market, that selects, develops and seeks ways to commercialize promising new Nordic lifescience innovations. Previously he was the president of the Karolinska Institute, a medical university, from 1995 to 2003, and was general director of the National Bacteriological Laboratory in Stockholm from 1987 to 1993. Dr. Wigzell is chairman of the board of the Stockholm School of Entrepreneurship. He is an elected member of several national academies, including the Swedish Royal Engineering Academy, Sweden; the Royal Academy of Science, Sweden; the Danish Academy of Arts and Letters; the American Academy of Arts and Sciences; the Finnish Science Society; and the European Molecular Biology Organization. In addition to serving as president of the Karolinska Institute, his academic career includes being Chairman, Nobel Prize Committee, Karolinska Institute and Distinguished External Advisory Professor, Ehime University, Japan. Additionally, Dr. Wigzell was appointed Chairman of the Nobel Assembly in 2000. He holds an M.D. and Ph.D. degree from the Karolinska Institute in Stockholm and he has received honorary doctors degrees at University “Tor Vergata” in Rome, Italy and Turku University in Finland.
Erin Cox

Basic Compensation

Name	Fiscal Year Total
William Goolsbee	--
Christopher Garabedian	3,857,810
Sandy Mahatme	--
David Howton	--
Edward Kaye	1,185,720
Michael Jacobsen	--
M. Kathleen Behrens	--
Anthony Chase	--
John Hodgman	--
Gil Price	--
Hans Wigzell	--
Erin Cox	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
William Goolsbee	0	0
Christopher Garabedian	0	0
Sandy Mahatme	0	0
David Howton	0	0
Edward Kaye	0	0
Michael Jacobsen	0	0
M. Kathleen Behrens	0	0
Anthony Chase	0	0
John Hodgman	0	0
Gil Price	0	0
Hans Wigzell	0	0
Erin Cox	0	0

Insider Trading

Name	Shares Traded	Price
CHASE ANTHONY R	1,600	$30.21
CHASE ANTHONY R	5,700	$29.70
CHASE ANTHONY R	1,600	$28.17
CHASE ANTHONY R	1,100	$29.04
CHASE ANTHONY R	800	$26.26
CHASE ANTHONY R	9,200	$25.65
BEHRENS M KATHLEEN	7,800	$14.91
CHASE ANTHONY R	13,300	$13.95
CHASE ANTHONY R	19,700	$14.79
BEHRENS M KATHLEEN	9,700	$14.58
WIGZELL HANS LENNART RUDOLF	833	$0.00
HODGMAN JOHN C	833	$0.00
CHASE ANTHONY R	833	$0.00
JACOBSEN MICHAEL A	7,500	$0.00
GOOLSBEE WILLIAM ALDEN	833	$0.00
BEHRENS M KATHLEEN	833	$0.00
PRICE BEN GIL	833	$0.00
CHRISTOPHER NISHAN GARABEDIAN	81,666	$0.00
PRICE BEN GIL	30,000	$1.30
CHRISTOPHER NISHAN GARABEDIAN	300,000	$0.58
CHASE ANTHONY R	20,000	$1.20
BEHRENS M KATHLEEN	5,000	$0.00
WIGZELL HANS LENNART RUDOLF	5,000	$0.00
GOOLSBEE WILLIAM ALDEN	5,000	$0.00
PRICE BEN GIL	5,000	$0.00

» Full list on Insider Trading

People: Sarepta Therapeutics Inc (SRPT.W)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: